Marks & Clerk has long been recognised as one of the leading patent, trade mark attorney and intellectual property law firms across the globe, with eight offices across the UK and a further eight in North America and the Asia-Pacific. We offer a comprehensive range of intellectual property services – covering patents, trade marks, designs and copyright. This includes obtaining protection worldwide, portfolio management, strategic and commercial advice, licensing and other contracts, enforcement, due diligence and litigation. . Renowned for our client-led approach, we are a top-tier firm, noted by Legal 500 for our life sciences practitioners and ‘strength in depth.’ From the capture and exploitation of an idea, to the enforcement or defence of rights in disputes Marks & Clerk is your expert partner to ensure your IP is protected and fully exploited. Today’s local is tomorrow’s global – and with our diverse team of practitioners, you’re always supported by a network of experts.
Ranked Tier 1 in Legal 500, Mathys & Squire is one of Europe's most highly regarded intellectual property firms. Founded in 1910, we have over 100 years of experience in the protection and commercialisation of intellectual property rights, leading the field with insight, innovation and quality.
With more than 60 qualified attorneys and offices in London, Manchester, Cambridge, Brighton, Oxford, York, the Midlands, Paris, Munich, Luxembourg and a team in China, we use a combination of our expertise, innovation and creativity to become part of our clients’ success stories and empower our teams to go above and beyond what clients expect when it comes to service delivery.
Mathys & Squire is pleased to offer One Nucleus members discounted rates for providing intellectual property support. Contact Dr Craig Titmus CTitmus@mathys-squire.com for more information.
With more than 60 qualified attorneys and offices in London, Manchester, Cambridge, Brighton, Oxford, York, the Midlands, Paris, Munich, Luxembourg and a team in China, we use a combination of our expertise, innovation and creativity to become part of our clients’ success stories and empower our teams to go above and beyond what clients expect when it comes to service delivery.
Mathys & Squire is pleased to offer One Nucleus members discounted rates for providing intellectual property support. Contact Dr Craig Titmus CTitmus@mathys-squire.com for more information.
Maxion Therapeutics Limited is a newly founded drug discovery company generating antibody-like therapeutics to target ion channel-driven diseases. A number of untreatable diseases such as chronic pain, autoimmune disorders and heart diseases involve ion channel dysfunction. Antibody drugs represent a potential solution but despite significant research spending clinical approval of this type of drug has not been achieved to date due to significant technical challenges. Maxion is addressing this unmet medical need with its proprietary Knotbody technology. wherein venom-derived cysteine-rich peptides (knottins) are fused into the surface of antibodies thereby combining the best features of both molecules.
Medicines Discovery Catapult (MDC) is an independent, not-for-profit organisation and part of the Catapult Network established by Innovate UK.
MDC's vision is to reshape drug discovery for patient benefit by transforming great UK science into better treatments through partnership.
MDC supports drug discovery innovators by making world-class expertise, facilities, complex technologies and advanced analytics accessible. We connect the life sciences ecosystem, driving a global focus on barriers to innovation in areas of unmet patient and technological need.
By industrialising new technologies to drive the adoption of new scientific tools and techniques, MDC enables successful medicines discovery.
More information: md.catapult.org.uk
MDC's vision is to reshape drug discovery for patient benefit by transforming great UK science into better treatments through partnership.
MDC supports drug discovery innovators by making world-class expertise, facilities, complex technologies and advanced analytics accessible. We connect the life sciences ecosystem, driving a global focus on barriers to innovation in areas of unmet patient and technological need.
By industrialising new technologies to drive the adoption of new scientific tools and techniques, MDC enables successful medicines discovery.
More information: md.catapult.org.uk
No data available
Consultancy on strategy, business development, fund-raising and general commercial matters in Life Sciences, particularly biotech.
Mestag is an immunotherapy company harnessing new insights into fibroblast-immune interactions to develop impactful treatments for patients. We are progressing a pipeline of sophisticated first-in-class antibodies designed to improve the lives of patients with cancer and inflammatory disease. Together with our collaboration partner Janssen Biotech, Inc. we are also identifying novel targets for future therapies.
Our founding investigators comprise global experts in inflammatory disease, cancer, computational biology and fibroblast biology from the University of Oxford, Brigham & Women’s Hospital, Harvard Medical School and Cold Spring Harbor Laboratory. We are supported by leading life science investors SV Health Investors, Johnson & Johnson Innovation – JJDC, Inc., Forbion, GV (formerly Google Ventures) and Northpond Ventures.
Mestag is headquartered in Cambridge, UK, and in 2021 was recognized on the Fierce 15 list of innovative biotechnology companies.
For further information please visit our website https://www.mestagtherapeutics.com
Our founding investigators comprise global experts in inflammatory disease, cancer, computational biology and fibroblast biology from the University of Oxford, Brigham & Women’s Hospital, Harvard Medical School and Cold Spring Harbor Laboratory. We are supported by leading life science investors SV Health Investors, Johnson & Johnson Innovation – JJDC, Inc., Forbion, GV (formerly Google Ventures) and Northpond Ventures.
Mestag is headquartered in Cambridge, UK, and in 2021 was recognized on the Fierce 15 list of innovative biotechnology companies.
For further information please visit our website https://www.mestagtherapeutics.com
Metrion Biosciences is a UK-based Contract Research Organization (CRO) focussed on delivering a range of high quality ion channel screening, cardiac safety profiling and drug discovery services on a fee-for-service or collaboration basis. Our aim is to provide ion channel electrophysiology expertise and high quality screening assays as part of a dedicated and flexible service tailored to customer requirements.. . Customers are able to access Metrion’s ion channel know-how and services at any point in their screening cascade. We offer a portfolio of services to add value to drug discovery programs by developing and de-risking ion channel modulators at all stages as they progress towards the clinic.
Mewburn Ellis LLP has one of the largest groups of patent attorneys specialising in biotechnology and life sciences in Europe. Our proactive approach and expertise reflect the high level work we do for a wide range of clients, from world renowned biotech companies based in the US and Europe, acting either directly or through their outside counsel, to small and medium sized companies, universities, charities, and funding bodies. We handle a substantial number of oppositions and appeals at the European patent office and have considerable expertise in drafting and prosecuting patent applications, due diligence work, infringement opinions, portfolio management and strategic patent advice.
No data available